Published in J Immunother on June 15, 2000
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature (2010) 5.05
EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol (2009) 1.40
Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. J Immunother Cancer (2014) 1.33
Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother (2008) 1.18
Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology (2012) 1.17
Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine. Clin Cancer Res (2009) 1.17
Functional heterogeneity of vaccine-induced CD8(+) T cells. J Immunol (2002) 1.07
Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines. J Immunother (2006) 1.00
Clinical applications of a peptide-based vaccine for glioblastoma. Neurosurg Clin N Am (2010) 0.87
Understanding the response to immunotherapy in humans. Springer Semin Immunopathol (2005) 0.83
Immunologic monitoring of cellular responses by dendritic/tumor cell fusion vaccines. J Biomed Biotechnol (2011) 0.77
Immunotherapy of melanoma. Immunology (2001) 0.76
Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma. Cancer Immunol Immunother (2016) 0.75
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med (1998) 7.48
Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes. Int J Cancer (1988) 3.66
CD56dimCD16neg cells are responsible for natural cytotoxicity against tumor targets. Leukemia (2005) 3.43
Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics (2001) 3.05
A comprehensive guide for the recognition and classification of distinct stages of hair follicle morphogenesis. J Invest Dermatol (1999) 2.92
Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction. Lancet (1991) 2.33
Improved outcome of zygomycosis in patients with hematological diseases? Leuk Lymphoma (2004) 2.20
Cortical inflammation in Alzheimer disease but not dementia with Lewy bodies. Arch Neurol (2000) 2.08
Immunoenzymometric assay of human glycogen phosphorylase isoenzyme BB in diagnosis of ischemic myocardial injury. Clin Chem (1995) 2.03
Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. Br J Haematol (1997) 1.90
Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin. Arch Dermatol (1998) 1.83
Decision aids: are they worth it? A systematic review. J Health Serv Res Policy (2001) 1.78
Auer rod-like intracytoplasmic inclusions in multiple myeloma. A case report and review of the literature. Int J Lab Hematol (2008) 1.77
Gabapentin enhances the analgesic effect of morphine in healthy volunteers. Anesth Analg (2000) 1.71
High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol (2004) 1.70
Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am (2000) 1.69
Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood (1988) 1.69
CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes. Neurology (2002) 1.68
UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. Clin Pharmacol Ther (2009) 1.67
Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer (2005) 1.66
Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. Ann Oncol (2014) 1.63
Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects. Ann Oncol (2005) 1.58
Melanocytes as "sensory" and regulatory cells in the epidermis. J Theor Biol (1993) 1.55
Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial. J Immunol Methods (2000) 1.53
Primary central nervous system lymphomas (PCNSL): MRI response criteria revised. Neurology (2005) 1.52
Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Ann Oncol (2007) 1.47
Primary central nervous system (CNS) lymphoma in immunocompetent patients. Ann Hematol (2002) 1.46
Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report. Neurology (2008) 1.44
Human mast cells produce IL-8. J Immunol (1993) 1.44
Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma. Onkologie (2004) 1.43
[Diagnosis and prognosis of gonadal damage after chemotherapy and irradiation]. Dtsch Med Wochenschr (1992) 1.41
Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma. J Pathol (1999) 1.40
Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas. Int J Cancer (1997) 1.40
[Resection of solitary liver metastases of malignant melanoma]. Chirurg (1995) 1.39
Haemophagocytosis in bone marrow rhabdomyosarcoma. Br J Haematol (1999) 1.39
Subtypes of T-cell chronic lymphatic leukemia. Cancer (1983) 1.39
TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. Br J Cancer (2013) 1.38
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 1.36
Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia (1995) 1.35
Significance of gene expression analysis in uveal melanoma in comparison to standard risk factors for risk assessment of subsequent metastases. Eye (Lond) (2007) 1.35
Alkaline phosphatase activity and localization during the murine hair cycle. Br J Dermatol (1994) 1.34
Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann Oncol (2011) 1.34
Increased expression of epidermal fatty acid binding protein, cofilin, and 14-3-3-sigma (stratifin) detected by two-dimensional gel electrophoresis, mass spectrometry and microsequencing of drug-resistant human adenocarcinoma of the pancreas. Electrophoresis (1999) 1.30
A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. Clin Cancer Res (1997) 1.29
Reduced serum 25-hydroxyvitamin D levels in stage IV melanoma patients. Anticancer Res (2009) 1.29
Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer. Cancer Res (2000) 1.28
Serum interleukin-8 (IL-8) is elevated in patients with metastatic melanoma and correlates with tumour load. Melanoma Res (1995) 1.28
Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay. Int J Cancer (1997) 1.28
Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood. J Immunol Methods (1997) 1.27
Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood (1996) 1.26
Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood (1999) 1.25
Serological detection of cutaneous T-cell lymphoma-associated antigens. Proc Natl Acad Sci U S A (2001) 1.24
The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice. Br J Cancer (1999) 1.22
Generation and cyclic remodeling of the hair follicle immune system in mice. J Invest Dermatol (1998) 1.22
Clinical and molecular characterization of early T-cell precursor leukemia: a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutations. Blood Cancer J (2012) 1.22
Increased expression of integrins on fibroblast-like synoviocytes from rheumatoid arthritis in vitro correlates with enhanced binding to extracellular matrix proteins. Ann Rheum Dis (1997) 1.21
Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer (2003) 1.21
Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol (1997) 1.20
A polymerase chain reaction-based semiquantitative assessment of malignant melanoma cells in peripheral blood. Cancer Res (1995) 1.19
Deficient IL-12p70 secretion by dendritic cells based on IL12B promoter genotype. Genes Immun (2004) 1.18
Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol (2006) 1.17
Biomarkers in melanoma. Ann Oncol (2009) 1.17
Drug-resistance in human melanoma. Int J Cancer (2001) 1.15
Flow cytometric determination of intracellular or secreted IFNgamma for the quantification of antigen reactive T cells. J Immunol Methods (2001) 1.15
Biliary proteins. Unique inhibitors of cholesterol crystal nucleation in human gallbladder bile. J Clin Invest (1984) 1.15
Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two-dimensional electrophoresis. Electrophoresis (2000) 1.14
[Prevention, diagnosis, therapy, and follow-up of lung cancer]. Pneumologie (2010) 1.14
Wilms' tumour gene 1 (WT1) in human neoplasia. Leukemia (2005) 1.12
Primary staging and follow-up in melanoma patients--monocenter evaluation of methods, costs and patient survival. Br J Cancer (2002) 1.11
Chlorinated hydrocarbons in adipose tissue of infants and toddlers: inventory and studies on their association with intake of mothers' milk. Eur J Pediatr (1984) 1.11
Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia (2004) 1.10
A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. Ann Oncol (2006) 1.10
A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer (2011) 1.10
Visceral leishmaniasis mimicking a flare of systemic lupus erythematosus. Clin Rheumatol (1991) 1.10
Phase I clinical and pharmacokinetic study of titanocene dichloride in adults with advanced solid tumors. Clin Cancer Res (1998) 1.09
A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol (2011) 1.08
Small molecules and targeted therapies in distant metastatic disease. Ann Oncol (2009) 1.08
Hematogenous spread of malignant melanoma cells in different stages of disease. J Invest Dermatol (1993) 1.08
Prevention, diagnosis, therapy, and follow-up of lung cancer: interdisciplinary guideline of the German Respiratory Society and the German Cancer Society. Pneumologie (2010) 1.06
Monitoring minimal residual disease by quantification of genomic chromosomal breakpoint sequences in acute leukemias with MLL aberrations. Leukemia (2006) 1.05
Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT. Int J Cancer (2001) 1.05
MRI in tracheal stenosis by innominate artery in children. Pediatr Radiol (1991) 1.04
Ten statements on the motivation of medical teachers to teach. Med Teach (1992) 1.04
Human dendritic cells infected by Listeria monocytogenes: induction of maturation, requirements for phagolysosomal escape and antigen presentation capacity. Eur J Immunol (2000) 1.04
Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors. Ann Oncol (2009) 1.04
Review of the incidence and clinical relevance of myeloid antigen-positive acute lymphoblastic leukemia. Leukemia (1991) 1.03
Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer (2002) 1.03
Dose-dependent severe cutaneous reactions to imatinib. Br J Cancer (2003) 1.03
In the queue for coronary artery bypass grafting: patients' perceptions of risk and 'maximal acceptable waiting time'. J Health Serv Res Policy (1999) 1.03